After almost two years of turnover in the FDA’s top ranks, the new appointments should help ease concerns about more turmoil ahead, one analyst said.
The drugmaker hopes to move the needle on challenging cancers and shore up its pipeline as it prepares for the Keytruda ...
As betting expands into clinical trial outcomes, drugmakers may need to look beyond employees and scrutinize outside partners ...
After two notable failures, the social anxiety R&D space gained a major player when Eli Lilly agreed to acquire AtaiBeckley ...
Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management ...
More than 25 years after it was declared eliminated, measles has surged back. But drug R&D is still in early stages and up ...
The FDA recently OK'd Gilead's novel HIV combo med, and cell therapy deals have fallen dramatically in two years.
Gilead’s new “Up to Date” campaign uses humor and dating scenarios to reach Black communities amid persistent gaps in HIV ...
CAR-T’s commercial challenge isn’t making bigger batches. It’s making thousands of patient-specific manufacturing runs behave ...
Two House Republicans are asking the FDA to increase oversight of China-generated clinical data after three trial deaths came ...
New leaders at GSK, Novo Nordisk and Sanofi are taking the reins at pivotal moments for three of pharma’s largest companies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results